TKNO Stock — Alpha Teknova, Inc.

Up next

Next earnings call

Nov 4, 2026 Est · unconfirmed · in 8 wks

Latest filing: 10-Q

filed Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 114 metrics

Revenue (TTM)

$43.70M

Trailing 12 months

Net income (TTM)

−$16.77M

Trailing 12 months

Revenue growth YoY

+18.5%

Year over year

Operating margin

-36.2%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-2.0%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+0.3%

Year over year · more shares

Price change (1Y)

+63.2%

Trailing year

Short interest

3.0%

Latest settlement · 5.0 days to cover

View all 114 metrics

AI Brief

Q2 FY26 earnings call · Aug 5, 2026

Q2 FY26

TL;DR. Teknova reported record Q2 2026 revenue of $12.2 million, up 18% year-over-year, and raised its full-year 2026 revenue guidance to $45–47 million (from $42–44 million) with improved free cash outflow expectations of less than $8 million.

Bullish

+ Q2 2026 revenue rose 18% YoY to a record $12.2 million, the highest quarterly revenue in company history
+ Company raised 2026 revenue guidance to $45–47 million (from $42–44 million), implying ~14% growth at midpoint vs. 6% prior
+ Improved 2026 free cash outflow outlook to less than $8 million for the full year
+ Q2 free cash outflow improved sharply to $0.6 million from $2.3 million YoY, the lowest since before the IPO
+ Gross margin expanded to 40.1% from 38.7% YoY on higher revenue

Bearish

− Cell and gene therapy orders were the only major market to decline due to order timing and softer biotech funding flow-through
− Net loss continued at $3.2 million (negative $0.06 per diluted share), though narrower than $3.6 million prior year
− Full-year gross margin guided to mid-to-upper 30s%, below the 40.1% posted in Q2, citing prior-year favorable comparison
− 2027 revenue outlook held unchanged at low $50 millions with no biotech funding tailwind embedded, delaying visibility

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Neutral Momentum Very Strong Sentiment Neutral Fundamentals Fair Quant / Vol Very High

Market backdrop VIX 14.5 · calm Equity put/call 0.58

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg +64%

above

Price vs 50-day avg +13%

above

RSI (14) 53

neutral

MACD trend Negative

52-week position 90%

near high

Volume (OBV) Bearish div.

distributing

Momentum

relative strength

Very Strong

1-month return +7%

trailing

6-month return +130%

trailing

YTD return +82%

this year

Relative strength +115%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $6 › 200d $4 — 50d above 200d

Institutional flow Accumulating

+3% holders QoQ · +12 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

2.96% of float · ▲ +6.6% MoM · 5.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

80 holders — near 3-yr high, broad support

Squeeze score 68

elevated · 0–100

Fundamentals

Fair

Revenue growth +7%

Y/Y

Gross margin 33%

expanding

EPS growth +44%

Y/Y

Free cash flow $-9.8M

Balance sheet $7.2M

net debt

Quant / Vol

risk profile

Very High

Volatility 81%

annualized · 1-yr

Max drawdown −69%

past year

ATR 6.7%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Beat or met 1 of last 2

Latest guidance · from the 8-K filed Aug 5, 2026

fiscal year ending December 31, 2026

Total revenue Initiated $45M – $47M

prior FY $40.52M midpoint +13.5% Y/Y

2026

Free Cash Outflow Non-GAAP up to $8M

Prior guidance period ended · from the 8-K filed Aug 13, 2024

Total revenue · fiscal year ending December 31, 2024 $35M – $38M

Free cash outflow · fiscal year ending December 31, 2024 up to $18M

Guided vs delivered · last 2 settled

Total revenue fiscal year ending December 31, 2024

guided $35M – $38M

guided $35M – $38M $37.75M In line

Total revenue 2022

guided $44M – $48M

guided $44M – $48M $41.42M Miss −10.0%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral

2 · 2 · 3

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+64% Bullish

Price vs 50-day avg

+13% Bullish

RSI (14)

53 Neutral

MACD trend

Negative Bearish

52-week position

90% Bullish

Volume (OBV)

Bearish div. Bearish

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $6 › 200d $4 — 50d above 200d

Institutional flow Accumulating

+3% holders QoQ · +12 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

2.96% of float · ▲ +6.6% MoM · 5.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

80 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $2 Now $7 · 90% Range high $7

vs 200-day avg +64% vs 50-day avg +13%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
TKNO Alpha Teknova, Inc. this stock	$371.52M	+82.1%	+7.4%	—	3.0%
JHPCY Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR	$66.37B	—	—	—	0.0%
TAK Takeda Pharmaceutical Co Ltd	$58.92B	+18.3%	—	—	0.1%
GALDY Galderma Group AG/ADR	$45.51B	-5.8%	—	—	0.0%
TEVA Teva Pharmaceutical Industries Ltd	$42.37B	+16.5%	+4.3%	59.6	3.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

80

% held: 17.0%
Net QoQ: +1.5M sh
Top holder: ROYCE & ASSOCIATES LP

Held Float

View

Held by Funds

Fund positions

79

View

Short & Settlement

Short Interest Rising

Shares short

1.6M

Days to cover: 5.0d
Change: +98.1K sh

View

Short Volume

Short vol %

38%

As of: Sep 4, 2026

Short Total

View

Fails to Deliver

FTD shares

5.5K

Value: $40.6K
As of: Aug 14, 2026

View

Off-Exchange

Off-exchange %

29.4%

Week of: Jul 27, 2026

Off-exch Lit

View

Financials

Revenue (FY)

$40.5M

Net income (FY): $-17.3M
EPS diluted: $-0.32

View

Filings

SEC Filings

Latest

10-Q

Filed: Aug 6, 2026
This year: 9

View

Proposed Sales

Value

$43.3K

Shares: 11.4K
Filed: Jun 13, 2023

View

Exempt Offerings

Offering

$20.9M

Filed: Jul 22, 2024

View

Earnings & Events

Earnings Calls Upcoming

Next call

Sep 29, 2026

Last call: Aug 5, 2026

View

Investor Relations

	5D	20D	120D	MTD	YTD
TKNO	-2.8%	+7.1%	+129.9%	-3.6%	+82.1%
SPY	+0.1%	-0.4%	+15.1%	+0.4%	+12.9%
vs SPY	-2.9%	+7.5%	+114.8%	-4.0%	+69.2%

TKNO · Alpha Teknova, Inc.

Price & Indicators

Up next

Metrics snapshot

AI Brief

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance